CAR T-Cell Therapy in India: A Hematologist’s Guide for International Patients

Introduction: Why CAR T-Cell Therapy Matters Today

Over the past decade, hematology has witnessed a shift that few of us anticipated at the turn of the millennium. For patients with relapsed or refractory blood cancers, particularly those who have exhausted chemotherapy, targeted therapy, and even stem cell transplantation, therapeutic options were once extremely limited. CAR T-cell therapy has altered that landscape.

As a hematologist involved in the management of advanced hematologic malignancies, I have seen how this personalized cellular therapy has changed outcomes for carefully selected patients. At the same time, I have also seen the confusion and uncertainty international patients face when exploring CAR T-cell therapy outside their home countries, questions around safety, eligibility, cost, logistics, and long-term outcomes are common and understandable.

This article aims to provide a clear, medically grounded overview of CAR T-cell therapy in India, specifically for international patients. The intent is not to promote a destination, but to explain where India currently stands from a clinical and scientific perspective, and what patients should realistically expect.

Understanding CAR T-Cell Therapy

What Is CAR T-Cell Therapy?

CAR T-cell therapy (short for Chimeric Antigen Receptor T-cell therapy) is a form of adoptive cellular immunotherapy. Unlike chemotherapy, which attacks rapidly dividing cells indiscriminately, CAR T therapy harnesses the patient’s own immune system to identify and destroy malignant cells. The process involves:

• Leukapheresis: T-cells are collected from the patient’s blood.
• Genetic modification: These T-cells are engineered in a laboratory to express a chimeric antigen receptor (CAR) that recognizes a specific antigen on cancer cells (commonly CD19 or BCMA).
• Cell expansion: Modified T-cells are multiplied to reach therapeutic doses.
• Reinfusion: After lymphodepleting chemotherapy, the engineered cells are infused back into the patient.

Once reinfused, these cells can proliferate in vivo and mount a sustained anti-tumor response.

Diseases Currently Treated with CAR T-Cell Therapy

Globally, CAR T-cell therapy has shown the strongest evidence in:

• Relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)
• Diffuse large B-cell lymphoma (DLBCL)
• Primary mediastinal B-cell lymphoma
• Mantle cell lymphoma
• Multiple myeloma (BCMA-targeted CAR T)
• Marginal zone lymphoma 
• Follicular lymphoma
• Waldernstrom macroglobulinemia

Pivotal trials such as ZUMA-1, JULIET, and ELIANA demonstrated complete remission rates ranging from 60% to over 80% in heavily pre-treated populations. More recently, BCMA-directed CAR T-cell therapies for multiple myeloma have shown deep and durable responses, even in triple-class refractory disease.

CAR T-Cell Therapy vs. Bone Marrow Transplant (BMT): Risk Profiling

From a clinical risk perspective, CAR T-cell therapy is generally considered safer than allogeneic stem cell transplantation, particularly in terms of early treatment-related mortality. Conventional stem cell transplant involves high-dose conditioning chemotherapy and carries a well-documented immediate life risk of approximately 5–10%, driven by complications such as severe infections, graft-versus-host disease, organ toxicity, and prolonged immunosuppression.

In contrast, CAR T-cell therapy does not require myeloablative conditioning or donor stem cells, and early mortality rates are significantly lower, especially when treatment is delivered in experienced centers with standardized toxicity management protocols. While CAR T therapy has its own risks, most notably cytokine release syndrome and transient neurotoxicity, these events are usually reversible with prompt intervention.

As a result, CAR T-cell therapy can often be safely offered to older or frail patients who would otherwise be considered poor candidates for stem cell transplantation, expanding access to potentially curative treatment in populations previously limited by transplant-related risk.

Why India Is Emerging in the CAR T-Cell Therapy Landscape

Clinical Infrastructure and Expertise

CAR T-cell therapy is not simply about access to a product; it requires a highly coordinated clinical ecosystem. This includes:

• Advanced hematology and bone marrow transplant units
• Access to intensive care facilities
• Neurology and infectious disease support
• Transfusion medicine and cell processing laboratories

In India, several tertiary centers now meet these requirements, supported by hematologists trained in cellular therapies and transplant medicine. Importantly, standardized protocols for toxicity grading and management, aligned with ASTCT and EBMT guidelines, are increasingly followed.

Regulatory and Scientific Progress in India

India has traditionally relied on imported CAR T-cell products, which significantly increased costs. Over the last few years, indigenously developed CAR T-cell therapies have entered clinical use under regulatory oversight.

Early Indian trials have demonstrated comparable safety and efficacy profiles to international data, particularly in CD19-positive lymphomas. While long-term follow-up data is still evolving, early remission rates and toxicity profiles are encouraging.

It is important for patients to understand that CAR T therapy in India is not experimental in an uncontrolled sense, it follows structured protocols, ethics committee approvals, and post-treatment surveillance.

Safety Profile: What Patients Should Realistically Expect

Cytokine Release Syndrome (CRS)

CRS is the most common acute toxicity following CAR T-cell infusion. It results from rapid immune activation and cytokine release.

• Symptoms range from fever and fatigue to hypotension and hypoxia
• Most cases are grade 1–2 and manageable
• Severe CRS occurs in a minority of patients

The availability of tocilizumab and corticosteroids has significantly reduced treatment-related mortality.

Neurotoxicity (ICANS)

Immune effector cell-associated neurotoxicity syndrome (ICANS) can present as:

• Confusion or altered consciousness
• Aphasia
• Seizures (rare)

ICANS is usually reversible with prompt intervention, but requires experienced monitoring teams.

Infection and Cytopenias

Prolonged low blood counts and immune suppression may occur, increasing infection risk. Long-term follow-up, vaccination planning, and infection prophylaxis are essential components of post-CAR T care.

Cost of CAR T-Cell Therapy: India vs Other Regions

Cost in India

For international patients, the typical cost of CAR T-cell therapy in India ranges between USD 42,000 and USD 55,000, depending on:

• Type of CAR construct used
• Duration of hospitalization and ICU care
• Complication management

This usually includes cell manufacturing, lymphodepleting chemotherapy, infusion, inpatient monitoring, and early follow-up.

Global Cost Comparison

• United States: USD 400,000–500,000 (excluding hospitalization)
• Australia: USD 250,000–350,000, with limited access and longer wait times
• Latin America: Limited availability; many patients are referred abroad
• Middle East: Variable access, often dependent on government approvals

The cost differential is largely driven by manufacturing economics, healthcare pricing structures, and regulatory overhead, not by dilution of clinical protocols.

Clinical Eligibility Checklist for International Patients

Before planning travel for CAR T-cell therapy, patients should meet most of the following medical criteria. Final eligibility is always determined after detailed case review.

Patients who do not initially meet criteria may still be eligible after optimization or further evaluation.

Final Thoughts

CAR T-cell therapy represents one of the most significant advances in modern hematology. For international patients, India offers a growing ecosystem where scientific rigor, regulatory oversight, and affordability intersect.

That said, CAR T therapy is not appropriate for everyone. Decisions should always be guided by disease biology, patient fitness, and center expertise, rather than cost alone. When used judiciously, CAR T-cell therapy can offer meaningful, and sometimes life-altering, outcomes.

Note: 

At Fortis Super Specialty Hospital, Shalimar Bagh, the hematology department is led by Dr. Akash Khandelwal along with a multidisciplinary team of trained hematologists, transplant physicians, intensivists, and specialized nursing staff. The department follows established national and international clinical guidelines, including evidence-based protocols for advanced therapies such as cellular therapy, bone marrow transplantation, and complex hematologic malignancy management.

Emphasis is placed on patient safety, standardized toxicity monitoring, infection control, and long-term follow-up, ensuring consistency in care delivery. With experience in managing both domestic and international patients, the team maintains structured clinical pathways that support comprehensive evaluation, treatment planning, and post-therapy care, while adhering to ethical practice standards and globally accepted treatment frameworks.

Travel, Visa, and Treatment Logistics for International Patients

For international patients considering CAR T-cell therapy in India, timely coordination and structured planning are essential to ensure both medical suitability and continuity of care. Patients are encouraged to seek expert guidance through HOSPIDIO, which works closely with treating physicians to support pre-treatment evaluation, treatment pathway planning, and post-therapy follow-up. Through HOSPIDIO, patients may arrange a video consultation with Dr. Akash Khandelwal for case review, eligibility assessment, and clinical discussion prior to travel.

In addition to facilitating medical opinions, the team assists with medical visa documentation, travel logistics, accommodation planning near the treatment center, and structured follow-up coordination after discharge, helping international patients navigate the process in a medically informed and organized manner.

Breakthroughs in Cancer Treatment: The Future of Oncology

World's Most Affordable CAR T-Cell Therapy in India: Everything You Need To Know

Bone Marrow Aspirate Concentrate (BMAC): A Regenerative Therapy for Joint and Tissue Repair

Recovering from Cancer? Here's How a Customized Diet Can Help Heal Your Body